Effects of Histone Deacetylase Inhibitors, Sodium Phenyl Butyrate and Vitamin B3, in Combination with Retinoic Acid on Granulocytic Differentiation of Human Promyelocytic Leukemia HL‐60 Cells

Abstract:  Water‐soluble vitamin B3, niacin, and its related compounds were suggested to be applicable for medical use. In this article, we examined the anti‐leukemic effects of two distinct histone deacetylase (HDAC1 and Sir2) inhibitors, sodium phenyl butyrate (PB) and vitamin B3, respectively, on human promyelocytic leukemia cells HL‐60, using HDACIs alone and in combination with all trans retinoic acid (RA). We demonstrated that the HDACI combinations exert different effects on cell cycle arrest and differentiation as determined by nitro blue reduction and the expression of the early myeloid differentiation marker CD11b. The most beneficial effects were found by use of 6‐h pretreatment with PB and vitamin B3 before the exposition to RA alone or in combination with vitamin B3, showing significant acceleration and a high level of granulocytic differentiation. The effects were associated with a rapid histone H4 acetylation and later histone H3 modifications. Our results suggest that the use of two HDACI altogether before the induction of differentiation and acting via chromatin remodeling may be promising for the treatment of acute promyelocytic leukemia.

[1]  C. Allis,et al.  New Insights into an Old Modification , 2000, Science.

[2]  C. Peschle,et al.  PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. , 2000, Blood.

[3]  A. Gineitis,et al.  Specific changes in the biosynthesis and acetylation of nucleosomal histones in the early stages of embryogenesis of sea urchin. , 1979, Experimental cell research.

[4]  R. Ohno,et al.  Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment. , 2005, Internal medicine.

[5]  K. Okumura,et al.  Induction of Differentiation in Human Promyelocytic Leukemia HL-60 Cell Line by Niacin-related Compounds , 2003, Bioscience, biotechnology, and biochemistry.

[6]  H. Koeffler,et al.  Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. , 2005, Experimental hematology.

[7]  T. Kouzarides.  Wellcome Trust Award Lecture. Chromatin-modifying enzymes in transcription and cancer. , 2003, Biochemical Society transactions.

[8]  S. Joel,et al.  Histone acetylation-mediated regulation of genes in leukaemic cells. , 2003, European journal of cancer.

[9]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[10]  M. Gorospe,et al.  Arsenic Trioxide Promotes Histone H3 Phosphoacetylation at the Chromatin of CASPASE-10 in Acute Promyelocytic Leukemia Cells* , 2002, The Journal of Biological Chemistry.

[11]  E. Seto,et al.  Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. , 2003, Current opinion in genetics & development.

[12]  J. Munro,et al.  Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. , 2004, Experimental cell research.

[13]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[14]  M. Uskoković,et al.  Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia , 2006, International journal of cancer.

[15]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[16]  C. Hurley.  Electrophoresis of histones: a modified Panyim and Chalkley system for slab gels. , 1977, Analytical biochemistry.

[17]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[18]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[19]  W. Bickmore,et al.  The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? , 2005, EMBO reports.

[20]  P. Pandolfi,et al.  Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.

[21]  P. Pandolfi,et al.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.

[22]  C. Allis,et al.  Signaling to Chromatin through Histone Modifications , 2000, Cell.

[23]  S. Collins,et al.  The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. , 1987, Blood.

[24]  G. Cox,et al.  ~ " " " ' l I ~ " " -" . : -· " J , 2006 .

[25]  T. Kouzarides.  Chromatin-modifying enzymes in transcription and cancer , 2003 .